LIXT (Lixte Biotechnology Holdings) Change In Payables And Accrued Expense : $-0.24 Mil (TTM As of Jun. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Lixte Biotechnology Holdings Change In Payables And Accrued Expense?

Lixte Biotechnology Holdings's Change In Payables And Accrued Expense for the quarter that ended in Jun. 2024 was $-0.12 Mil. It means Lixte Biotechnology Holdings's Accounts Payable & Accrued Expense declined by $0.12 Mil from Mar. 2024 to Jun. 2024 .

Lixte Biotechnology Holdings's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $-0.07 Mil. It means Lixte Biotechnology Holdings's Accounts Payable & Accrued Expense declined by $0.07 Mil from Dec. 2022 to Dec. 2023 .

Lixte Biotechnology Holdings Change In Payables And Accrued Expense Historical Data

The historical data trend for Lixte Biotechnology Holdings's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings Change In Payables And Accrued Expense Chart

Lixte Biotechnology Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

-0.05

0.05

0.04

-0.07

Lixte Biotechnology Holdings Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															0.14	-0.15	-0.07	0.09	-0.12

Lixte Biotechnology Holdings Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.24 Mil.

Lixte Biotechnology Holdings Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Lixte Biotechnology Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (NAS:LIXT) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101

Website

https://www.lixte.com

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Executives

Rene Bernards	director	KONINGSVAREN 37, ABCOUDE P7 1391AD
Van Der Baan Bastiaan Jeroen	director	HOGEWEG 4-H, AMSTERDAM P7 1098CB
Eric Forman	10 percent owner	117 E. 29TH ST., APT. 5A, NEW YORK NY 10016
Regina Brown	director	248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733
Glenn Krinsky	10 percent owner	C/O SRKP 1, INC., 1900 AVENUE OF THE STARS, SUITE 310, LOS ANGELES CA 90067
Yun Yen	director	1301 OAKLAWN ROAD, ARCADIA CA 91006
Robert Greenberg	10 percent owner	SKECHERS USA INC, 228 MANHATTAN BEACH BLVD, MANHATTAN BEACH CA 90266
Gil Schwartzberg	10 percent owner	269 S. BEVERLY DR., #1315, BEVERLY HILLS CA 90212
Philip F Palmedo	director	1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067
John S Kovach	director, 10 percent owner, officer: Pres., CFO & Secty	1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067
Stephen J. Forman	director	248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733
Hung Tak Ho	10 percent owner	MAYFAIR BY THE SEA II, TOWER T8, 1/F, UNIT A, 21 FO CHUN ROAD, PAK SHEK KOK, TAIPO K3 00000
Robert N Weingarten	officer: Vice President and CFO	5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367
James Miser	officer: Chief Medical Officer	680 E COLORADO BLVD., SUITE 180, PASADENA CA 91101
Jane Merrill Riggs	10 percent owner	4852 SAINT ANDRES AVENUE, LA VERNE CA 91750